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The Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), undertaken in people with type 1 and 2 diabetes, respectively (1, 2 ) , established the significance of glycohemoglobin (gHb), and in particular hemoglobin A 1c (HbA 1c ), as a prognostic indicator for long-term micro-and macrovascular complications. However, the HbA 1c measured during the DCCT and UKPDS represents a gHb fraction characterized by its retention time on cation-exchange HPLC rather than its unique chemical structure (deoxyfructosylhemoglobin). Accordingly, the DCCT HbA 1c procedure represents a selective, but not a specific assay method (3 ).
Because no definitive or reference method exists for quantification of HbA 1c (4 ), the American Diabetes Association (ADA), in collaboration with the Association of Clinical Chemists, implemented the National Glycohemoglobin Standardization Program (NGSP) (5 ) to standardize HbA 1c values determined by methods different from that used in the DCCT. The ADA (6 ) now states that their recommended HbA 1c thresholds, with respect to patient management goals, are valid only for NGSP-certified methods.
The variability of HbA 1c measurements depends on both analytical and biological variation. However, because HbA 1c concentrations are used for individual patient management, only analytical imprecision and within-person biological variation (s i 2 ) are relevant. Whereas the NGSP (5 ) states that within-person HbA 1c variance is negligible, previous studies (7, 8 ) have reported s i estimates of 0.17-0.79, and investigations measuring gHb (9 ) or HbA 1 (10 ) have reported values between 0.45 and 1.03. Accordingly, both analytical and within-person variability, but particularly the latter, increase measurement uncertainty and, therefore, the potential for clinical misinterpretation at ADA-specified HbA 1c thresholds.
The following definitions are provided to avoid ambiguity with respect to terminology:
Within-person variance (s i 2 ): the degree of random fluctuation of values around a person's homeostatic set-point for a particular biological analyte. For people with diabetes, the HbA 1c homeostatic set-point is controlled by dietary and/or pharmacologic treatment, and not by the normal physiologic mechanism. Repeatability (s o ): closeness of agreement between successive results obtained with the same method on identical test material and under the same conditions (same operator, same apparatus, same laboratory, and same time). Reproducibility (s x ): closeness of agreement between individual results obtained with the same method on Serial HbA 1c measurements were made in a cohort of 26 diabetic patients, in stable metabolic control, taking part in a 48-week multicenter trial (11 ) . The mean number of specimens per patient was 7.2 (range, 6 -9). All gHb determinations were performed with an affinity microcolumn assay (12 ) , and results were converted to HbA 1c percent-equivalents based on an algorithm originally derived by comparison (n ϭ 186) with a HPLC method (13 ) . During the trial period (2 years), s a for the affinity column method was 0.47 at a mean HbA 1c concentration of 9.6%. The standard error of the estimate (s e ), calculated by nonparametric regression (HbA 1c vs time) (14 ) , was used to determine long-term variability associated with each patient's serial HbA 1c measurements. The corresponding mean s e was determined as the root mean square of the individual estimates (15 ) .
Four different blood samples (ϳ100 L of each in a sealed ampoule), spanning HbA 1c concentrations of ϳ6 -13%, were hand-delivered on the same day to the five pathology laboratories performing physician-referred HbA 1c assays in this State. The protocol (16 ) requires that all samples be analyzed in duplicate within a single analytical run. Three laboratories used Bio-Rad Variant HPLCs (NGSP-certified), and two used Pharmacia Mono S column HPLC systems (13 ) traceable to the Bio-Rad Diamat HPLC method. The cooperative trial method was defined as ion-exchange HPLC.
Routine data analysis was performed using SPSS for Windows, Release 10.0.7 (SPSS Inc.) and the Cbstat program (http://www.cbstat.com). The procedures described by Steiner (16 ) were used to calculate the corresponding estimates of repeatability and reproducibility for the interlaboratory study.
The individual estimates of s e were not statistically related to the respective baseline HbA 1c concentrations (Kendall tau-b, 0.039; P ϭ 0.8). The overall mean s e was 0.65, and given s e 2 ϭ s i 2 ϩ s a 2 , the within-person standard deviation s i ϭ ͌ (s e 2 Ϫ s a 2 ) ϭ 0.44. For the interlaboratory study, the respective mean HbA 1c values for the four samples were 5.8%, 7.8%, 10.4%, and 12.8%, and no laboratory showed consistently high or low HbA 1c values, based on a method that ranks the sum of replicates. Similarly, no abnormal data were identified within the four samples when we used the Dixon test, and experimental variation between laboratories and between replicates was homogeneous. ANOVA established a significant variance ratio between laboratories (F 4,12 ϭ 6.5; P Ͻ0.05) and for laboratory-sample interaction (F 12,20 ϭ 30.7; P Ͻ0.01). Solving standard ANOVA equations (16 ) , we calculated the between-laboratory (s L 2 ) and laboratory-sample interaction (s LS 2 ) variances as 0.143 2 and 0.12 2 , respectively. The reproducibility (s x ), or variation arising from different operators, instruments, and laboratories is then given by: (1) and calculated as 0.19. Accordingly, among the five laboratories, 57% of total variance is between-laboratory, 40% is attributable to laboratory-sample interaction, and 3% is attributable to repeatability. The total error variance associated with the five HbA 1c assays is therefore given by:
and is calculated as 0.48 2 , of which s i 2 contributes 84%. The design of the present cooperative trial, however, did not allow an estimate of long-term repeatability.
Knowledge of s E allows estimation of the range within which the true value lies at a reported HbA 1c value, assuming that biological variability is that of a typical patient. Moreover, because s x 2 Ͻ Ͻ s i 2 , total error can be decreased more by analyzing additional specimens on the same patient than by performing more assays on the same specimen. This is highlighted in Table 1 , which summarizes confidence ranges at different probabilities for analysis of one and two specimens. Accordingly, from Table 1 , to be 80% confident that the ADA goal of Ͻ7.0% has been achieved (single specimen), the measured HbA 1c concentration should be Ͻ6.4%. A 95% confidence for the same goal requires a mean HbA 1c concentration (two specimens) Ͻ6.3%. Alternatively, to be 90% confident (single specimen) that the ADA Ͼ8.0% intervention threshold has been exceeded, a measured HbA 1c concentration Ն8.7% is necessary.
Although the goal of the NGSP is to minimize bias between the DCCT and other HbA 1c methods, and thereby allow uniform application of DCCT-derived HbA 1c results, measurement uncertainty at ADA clinical decision-making thresholds has not been thoroughly addressed. In particular, failure to acknowledge the magnitude of within-person variation produces a significant underestimation of total measurement error. Our estimate of s i (0.44) is remarkably similar to the value of 0.41 reported previously by Hyltoft Petersen et al. (7 ) , although both the experimental design and HbA 1c methodology were different. In contrast, Kolatkar et al. (8 ) reported lower values of 0.17 and 0.29 for 3-and 12-month study periods, respectively, where all patients were intensively treated and had HbA 1c concentrations maintained at Ͻ7.0%. Our findings for the five HPLC methods indicated that reproducibility was much less than within-person biological variation. However, the confidence intervals around a measured HbA 1c concentration were still wide (Table 1) in comparison with the small difference (1%) between the ADA HbA 1c management thresholds. The potential impact of measurement uncertainty on HbA 1c thresholds has been discussed previously by Lytken Larsen et al. (17 ) .
The most recently posted results for the College of American Pathologists HbA 1c survey (18 ) show reproducibility values for certified methods between 0.19 and 0.85; the most common method (n ϭ 335), the Abbott IMx (uncertified), had s x ϭ 0.54. Only HPLC methods had s x Ͻ0.25, whereas all multianalyte methods had s x Ն0.43. Minimal analytical performance has been proposed as 0.75s i (19 ) , which based on our results is 0.33. However, the actual DCCT HbA 1c procedure had a repeatability of 0.15 on masked split-duplicate specimens, whereas the long-term internal quality control showed a s a of ϳ0.40 (20 ) .
In summary, the degree of within-person biological variation associated with HbA 1c determinations significantly increases the total measurement error. If a HbA 1c assay of high reproducibility is not used, the dispersion range of true HbA 1c values around the mean true biological set-point will be so wide that the ADA management thresholds may become unworkable. Although the NGSP has significantly reduced intermethod bias, only some HPLC methods currently meet the required analytical performance (19 ) .
